Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline

Hagens Berman Sobol Shapiro LLP notified Aardvark Therapeutics (NASDAQ: AARD) investors of a pending securities class action covering purchasers traceable to the February 13, 2025 IPO and the February 13, 2025 to May 14, 2026 class period, with an October 13, 2026 lead plaintiff deadline. The complaint alleges Aardvark misled investors about ARD-101's safety, citing reversible cardiac observations (QRS prolongation) at above-target doses that preceded a voluntary Phase 3 HERO trial pause in February 2026 and a full FDA clinical hold on the ARD-101 IND in May 2026. Per the release, AARD shares fell over 56% on the trial pause announcement and another 32.1% on the clinical hold disclosure.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.